Drug intelligence / Profile preview

fungerp analogs

Development stage: Preclinical
Lead developer: Scynexis
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Fungerp analogs are a series of small molecule antifungal triterpenoids under development by Scynexis in collaboration with the National Institutes of Health (NIH). The program, known as the Fungal Emergency Response Program (Fungerp), is focused on the treatment of resistant fungal infections, including those caused by potential biothreat agents. The development is supported by a grant of approximately $7 million from the NIH's Chemical Threat Evaluation and Response (CTER) program. These analogs are currently in the IND-enabling phase of development and are designed to address unmet needs in the treatment of multidrug-resistant fungal pathogens.

Other names: antifungal triterpenoidsFungerp

Targets

GLUL (Glutamine synthetase)

Beyond the preview

Go deeper on fungerp analogs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fungerp analogs.

Explore the full profile